BACKGROUND AND AIMS: Insulin resistance is a key factor in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). We evaluated the importance of subcutaneous abdominal adipose tissue (SAAT) inflammation and both plasma and SAAT-derived exosomes in regulating insulin sensitivity in people with obesity and NAFLD. METHODS: Adipose tissue inflammation (macrophage and T-cell content and expression of proinflammatory cytokines), liver and whole-body insulin sensitivity (assessed using a hyperinsulinemic-euglycemic clamp and glucose tracer infusion), and 24-hour serial plasma cytokine concentrations were evaluated in 3 groups stratified by adiposity and intrahepatic triglyceride (IHTG) content: (1) lean with normal IHTG content (LEAN; N = 14); (2) obese with normal IHTG content (OB-NL; N = 28); and (3) obese with NAFLD (OB-NAFLD; N = 28). The effect of plasma and SAAT-derived exosomes on insulin-stimulated Akt phosphorylation in human skeletal muscle myotubes and mouse primary hepatocytes was assessed in a subset of participants. RESULTS: Proinflammatory macrophages, proinflammatory CD4 and CD8 T-cell populations, and gene expression of several cytokines in SAAT were greater in the OB-NAFLD than the OB-NL and LEAN groups. However, with the exception of PAI-1, which was greater in the OB-NAFLD than the LEAN and OB-NL groups, 24-hour plasma cytokine concentration areas-under-the-curve were not different between groups. The percentage of proinflammatory macrophages and plasma PAI-1 concentration areas-under-the-curve were inversely correlated with both hepatic and whole-body insulin sensitivity. Compared with exosomes from OB-NL participants, plasma and SAAT-derived exosomes from the OB-NAFLD group decreased insulin signaling in myotubes and hepatocytes. CONCLUSIONS: Systemic insulin resistance in people with obesity and NAFLD is associated with increased plasma PAI-1 concentrations and both plasma and SAAT-derived exosomes. ClinicalTrials.gov number: NCT02706262 (https://clinicaltrials.gov/ct2/show/NCT02706262).
BACKGROUND AND AIMS: Insulin resistance is a key factor in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). We evaluated the importance of subcutaneous abdominal adipose tissue (SAAT) inflammation and both plasma and SAAT-derived exosomes in regulating insulin sensitivity in people with obesity and NAFLD. METHODS: Adipose tissue inflammation (macrophage and T-cell content and expression of proinflammatory cytokines), liver and whole-body insulin sensitivity (assessed using a hyperinsulinemic-euglycemic clamp and glucose tracer infusion), and 24-hour serial plasma cytokine concentrations were evaluated in 3 groups stratified by adiposity and intrahepatic triglyceride (IHTG) content: (1) lean with normal IHTG content (LEAN; N = 14); (2) obese with normal IHTG content (OB-NL; N = 28); and (3) obese with NAFLD (OB-NAFLD; N = 28). The effect of plasma and SAAT-derived exosomes on insulin-stimulated Akt phosphorylation in human skeletal muscle myotubes and mouse primary hepatocytes was assessed in a subset of participants. RESULTS: Proinflammatory macrophages, proinflammatory CD4 and CD8 T-cell populations, and gene expression of several cytokines in SAAT were greater in the OB-NAFLD than the OB-NL and LEAN groups. However, with the exception of PAI-1, which was greater in the OB-NAFLD than the LEAN and OB-NL groups, 24-hour plasma cytokine concentration areas-under-the-curve were not different between groups. The percentage of proinflammatory macrophages and plasma PAI-1 concentration areas-under-the-curve were inversely correlated with both hepatic and whole-body insulin sensitivity. Compared with exosomes from OB-NL participants, plasma and SAAT-derived exosomes from the OB-NAFLD group decreased insulin signaling in myotubes and hepatocytes. CONCLUSIONS: Systemic insulin resistance in people with obesity and NAFLD is associated with increased plasma PAI-1 concentrations and both plasma and SAAT-derived exosomes. ClinicalTrials.gov number: NCT02706262 (https://clinicaltrials.gov/ct2/show/NCT02706262).
Authors: Nora Klöting; Mathias Fasshauer; Arne Dietrich; Peter Kovacs; Michael R Schön; Matthias Kern; Michael Stumvoll; Matthias Blüher Journal: Am J Physiol Endocrinol Metab Date: 2010-06-22 Impact factor: 4.310
Authors: David A Hill; Hee-Woong Lim; Yong Hoon Kim; Wesley Y Ho; Yee Hoon Foong; Victoria L Nelson; Hoang C B Nguyen; Kavya Chegireddy; Jihoon Kim; Andreas Habertheuer; Prashanth Vallabhajosyula; Taku Kambayashi; Kyoung-Jae Won; Mitchell A Lazar Journal: Proc Natl Acad Sci U S A Date: 2018-05-14 Impact factor: 11.205
Authors: David W Freeman; Nicole Noren Hooten; Erez Eitan; Jamal Green; Nicolle A Mode; Monica Bodogai; Yongqing Zhang; Elin Lehrmann; Alan B Zonderman; Arya Biragyn; Josephine Egan; Kevin G Becker; Mark P Mattson; Ngozi Ejiogu; Michele K Evans Journal: Diabetes Date: 2018-05-02 Impact factor: 9.337
Authors: Larissa Cristina Fontenelle; Mickael de Paiva Sousa; Loanne Rocha Dos Santos; Bruna Emanuele Pereira Cardoso; Thayanne Gabryelle Visgueira de Sousa; Tamires da Cunha Soares; Stéfany Rodrigues de Sousa Melo; Jennifer Beatriz Silva Morais; Thaline Milany da Silva Dias; Francisco Erasmo de Oliveira; Débora Cavalcante Braz; João Marcelo de Castro E Sousa; Francisco Leonardo Torres-Leal; Gilberto Simeone Henriques; Dilina do Nascimento Marreiro Journal: Biol Trace Elem Res Date: 2022-04-06 Impact factor: 3.738
Authors: Han-Chow E Koh; Stephan van Vliet; Chao Cao; Bruce W Patterson; Dominic N Reeds; Richard Laforest; Robert J Gropler; Yo-El S Ju; Bettina Mittendorfer Journal: Eur J Endocrinol Date: 2022-02-23 Impact factor: 6.558
Authors: Wenyu Xiang; Shuai Han; Cuili Wang; Hongjun Chen; Lingling Shen; Tingting Zhu; Kai Wang; Wenjie Wei; Jing Qin; Nelli Shushakova; Song Rong; Hermann Haller; Hong Jiang; Jianghua Chen Journal: Front Med (Lausanne) Date: 2022-01-07